Skip to main content

Agreements Establish Credit Facilities of up to $2B for Thermo Fisher Scientific

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has entered into two agreements establishing credit facilities for up to $2 billion, the firm disclosed after the close of the market on Friday.

The agreements, both reached April 11, replace earlier similar agreements, Thermo Fisher said.

In a document filed with the US Securities and Exchange Commission, Thermo Fisher said one agreement is for a five-year senior unsecured revolving facility for an initial principal amount of $1 billion with an optional $500 million increase. The facility has a number of lenders, including Bank of America, Goldman Sachs Bank USA, JP Morgan Chase Bank, Morgan Stanley Bank, and Deutsche Bank, and others.

Also, Thermo Fisher has entered into a 364-day credit agreement for a senior unsecured revolving credit facility for $500 million. Lenders for that facility also include Bank of America, Goldman Sachs Bank USA, JP Morgan Chase Bank, Morgan Stanley Bank, and Deutsche Bank, and others.

Proceeds from both agreements may be used for working capital purposes, capital expenditures, acquisitions, repurchases of stock, and other general corporate purposes.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.